Hemlibra emicizumab

Zero-bleed euphoria is Hemlibra's strongest retention asset; cost barriers and the aPCC interaction warning are the two sharpest adherence-leak and switch-risk moments to address proactively.

• Patients describe Hemlibra as transformative, reporting zero bleeds for months after decades of frequent factor infusions, with subcutaneous dosing freeing them from IV access and rigid schedules.
• Cost and insurance step-therapy requirements are the dominant pre-start barriers, with list prices near $47,000 per month generating anxiety even when co-pay programs reduce out-of-pocket exposure substantially.
• The aPCC/FEIBA interaction warning is a persistent patient education gap: forum discussions show confusion about which bypass agents are safe during breakthrough bleeds while on Hemlibra.
• Investigational Mim8 with its pen-injector device and direct-switch data is generating awareness in the hemophilia community, representing a nascent but real future retention risk for Genentech.